Business Wire

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration

6.3.2026 21:23:00 EET | Business Wire | Press release

Share

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release.

1. 335 million locked-up shares — but two different categories

Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations.

A. 159 million shares (48% of locked-up shares) Depository receipt holders:

(i) ~97 million shares (30% of locked-up shares) — affiliate holders held through depositary receipts

Approximately 97 million shares (29% of all locked-up shares) are held by affiliates of the Company — a legal category that includes certain major institutional shareholders, executive officers, and members of the Board of Directors. Affiliate holders are subject to ongoing trading volume restrictions under Rule 144 of the US Securities Act that exist independently of, and are not removed by, the expiration of the IPO lock-up. Any affiliate wishing to sell shares is required to file the appropriate forms with the SEC concurrently with the placing of an order to execute a sale. As of the date of this release, no such filings have been made by any affiliate of the Company.

(ii) ~62 million shares (18% of lock-up shares) - non-affiliate shareholders held through depositary receipts

Approximately 62 million shares (18% of all locked-up shares) are held by non-affiliate shareholders of the Company through depositary receipts. These holders have elected to hold Depositary Receipts — a choice that allows them to retain their Class B share voting rights. Class B shares carry ten votes per share, compared to one vote per share for the Class A ordinary shares traded on the NYSE. Conversion to Depositary Receipts means these shares are not being transferred to broker-dealer accounts for open-market trading.

B. ~177 million shares — non-affiliate holders. The remaining approximately 177 million shares are held by non-affiliate pre-IPO shareholders whose lock-up expires March 9. Because Klarna Group plc is incorporated in England and Wales, pre-IPO ordinary shares are not held in DTC-eligible form. Before any such share can be sold through a US broker-dealer other than Computershare, the holder must complete a conversion process administered by Computershare, Klarna's transfer agent, involving the submission of a Letter of Transmittal. We are advised that Computershare's minimum processing time following receipt of a completed Letter of Transmittal is approximately 7 to 10 business days.

2. Status of the 177 million shares

3 million shares (1% of the 335 million) - Extended lock-up

Employees who received shares less than 6 months before the IPO hold what are known as "restricted securities" under the Securities Act of 1933. These shares carry a restrictive legend and cannot be freely transferred to a broker or sold publicly until certain conditions are met.

82 million shares (25% of the 335 million) — conversion process not initiated. These holders have not yet submitted a Letter of Transmittal to Computershare. Their shares cannot be transferred to a brokerage account until they do so and Computershare completes processing — a minimum of approximately 7 to 10 business days from submission. Holders who take no action with Computershare will continue to hold their shares in pre-IPO form and retain their existing share rights.

17 million shares (5%) — holders have elected to retain high-vote shares, not sell. These holders have submitted a Letter of Transmittal and elected to convert into Depositary Receipts — a choice that allows them to retain their Class B share voting rights. Class B shares carry ten votes per share, compared to one vote per share for the Class A ordinary shares traded on the NYSE. Conversion to Depositary Receipts means these shares are not being transferred to broker-dealer accounts for open-market trading.

25 million shares (7%) - transmittal received by Computershare. These holders have submitted a Letter of Transmittal yet to be processed by Computershare. These shares may become available for trading upon settlement. We cannot speak to the trading intentions of any of these holders.

50 million shares (15%) - transmittal received by Computershare and have opted to transfer to broker. These shares may become available for trading upon settlement. We cannot speak to the trading intentions of any of these holders.

3. The B-share voting right disincentive

Any pre-IPO shareholder who has not yet submitted a Letter of Transmittal holds Class B ordinary shares carrying ten votes per share. Initiating the conversion process to a broker-dealer account results in the permanent and irrevocable loss of Class B voting rights. This is a material structural consideration for any long-term shareholder independently of any trading intention.

4. Employees already had the opportunity to sell at IPO

Coverage suggesting that Monday represents the first opportunity for Klarna insiders and employees to sell is inaccurate. In connection with the September 2025 IPO, Klarna facilitated a liquidity programme under which employees holding vested RSUs were permitted to convert those awards into tradable ordinary shares and sell them shortly after trading commenced in the IPO, explicitly exempt from the standard six-month IPO lock-up. Employees were permitted to sell through September 30, 2025, with trading thereafter available during quarterly windows.

Additionally, during the IPO, existing shareholders sold 34.4m shares at $40.00 per ordinary share.

Shareholders who wished to realise liquidity have had multiple prior opportunities to do so. March 9, 2026 is not the first opportunity for pre-IPO shareholders to sell.

5. Summary

  • Depository receipts (affiliate and non-affiliate): ~159M shares (48%)
  • Letter of Transmittal not submitted: ~82M shares (24%)
  • Elected Depositary Receipts: ~17M shares (5%)
  • Opted to transfer to broker: ~50M shares (15%)
  • To be processed by Computershare: ~25M shares (7%)
  • Extended employee lock-up: ~3M shares (1%)
  • Total: 335M shares (100%)

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements regarding our future financial performance, share structure and applicable processes, business strategy, growth objectives, market opportunities, operational plans, including the outcome of legal cases. Words such as "believe," "expect," "anticipate," "intend," "plan," "will," "may," "could," "estimate," and similar expressions identify forward-looking statements.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied, including risks related to:

  • Our ability to retain and grow consumer and merchant relationships;
  • Competition and technological developments;
  • Regulatory compliance and licensing requirements;
  • Our ability to achieve expected benefits from our funding arrangements;
  • Credit risk management and funding availability;
  • General economic conditions and market volatility; and
  • Our ability to expand into new markets and products.

Forward-looking statements reflect our views as of the date of this release and are based on information currently available to us. We undertake no obligation to update any forward-looking statements, except as required by law. Actual results may differ materially from those anticipated. Investors should not place undue reliance on these forward-looking statements and should review the risk factors in our filings with the SEC for a more complete discussion of risks.

About Klarna

Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna users and 3.4 million transactions per day, Klarna’s AI-powered payments and commerce network is empowering people to pay smarter with a mission to be available everywhere for everything. Consumers can pay with Klarna online, in-store and through Apple Pay & Google Pay. More than 966,000 retailers trust Klarna’s innovative solutions to drive growth and loyalty, including Uber, H&M, Saks, Sephora, Macy’s, Ikea, Expedia Group, Nike and Airbnb. Klarna is listed on the New York Stock Exchange (NYSE: KLAR). For more information, visit Klarna.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260306414202/en/

Contacts

press@klarna.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release

Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For

Hytera Announces 450Connect Whitelisting of PNC660 450MHz at MWC 20266.3.2026 14:02:00 EET | Press release

Hytera, a leading global provider of critical communications technologies and solutions, announced that its mission-critical smart device, the PNC660 450MHz, has been granted whitelist certification by 450Connect during the Mobile World Congress 2026 (MWC26), held from March 2 to 5 in Barcelona, Spain. This certification authorizes the device for full commercial deployment across European 450MHz private broadband networks, marking a significant milestone for Hytera in delivering reliable, secure, and robust communication solutions to energy providers and other critical infrastructure sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305205209/en/ Hytera launches the MCX Smart Device PNC660 450MHz 450Connect is the exclusive licensee and operator of the nationwide 450MHz radio network in Germany and across Europe. Its whitelist program enforces stringent evaluation criteria covering device compatibility, network inte

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye